PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.88%
Revenue growth at 75-90% of 9843.T's 5.46%. Bill Ackman would push for innovation or market expansion to catch up.
5.75%
Gross profit growth similar to 9843.T's 5.46%. Walter Schloss would assume both firms track common industry trends.
12.67%
EBIT growth 75-90% of 9843.T's 16.48%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
12.67%
Operating income growth at 50-75% of 9843.T's 21.83%. Martin Whitman would doubt the firm’s ability to compete efficiently.
-3.27%
Negative net income growth while 9843.T stands at 18.86%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3.27%
Negative EPS growth while 9843.T is at 18.76%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3.27%
Negative diluted EPS growth while 9843.T is at 18.76%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 9843.T is at 0.09%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 9843.T is at 0.09%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.34%
10Y revenue/share CAGR under 50% of 9843.T's 123.30%. Michael Burry would suspect a lasting competitive disadvantage.
48.58%
5Y revenue/share CAGR similar to 9843.T's 45.17%. Walter Schloss might see both companies benefiting from the same mid-term trends.
25.30%
3Y revenue/share CAGR at 75-90% of 9843.T's 28.71%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.18%
Below 50% of 9843.T's 145.96%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
39.74%
5Y net income/share CAGR 1.25-1.5x 9843.T's 29.20%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
28.36%
3Y net income/share CAGR 1.25-1.5x 9843.T's 21.85%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
151.08%
10Y equity/share CAGR at 50-75% of 9843.T's 300.93%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
101.86%
5Y equity/share CAGR 1.25-1.5x 9843.T's 84.35%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
50.02%
3Y equity/share CAGR similar to 9843.T's 46.16%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.35%
AR growth well above 9843.T's 30.83%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.20%
Inventory is declining while 9843.T stands at 6.81%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.82%
Asset growth at 50-75% of 9843.T's 5.35%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
2.57%
50-75% of 9843.T's 3.54%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-57.60%
We’re deleveraging while 9843.T stands at 31.36%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
83.47%
We expand SG&A while 9843.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.